

MATILDE regimen followed by radiotherapy is an active lymphomas

Neurology

66, 1435-1438

DOI: [10.1212/01.wnl.0000210464.94122.e1](https://doi.org/10.1212/01.wnl.0000210464.94122.e1)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Chemotherapy for primary central nervous system lymphoma. <i>Neurosurgical Focus</i> , 2006, 21, 1-8.	1.0	25
2	Combined Immunochemotherapy With Reduced Whole-Brain Radiotherapy for Newly Diagnosed Primary CNS Lymphoma. <i>Journal of Clinical Oncology</i> , 2007, 25, 4730-4735.	0.8	359
3	A Virtual Tissue Bank for Primary Central Nervous System Lymphomas in Immunocompetent Individuals. <i>Pathobiology</i> , 2007, 74, 264-269.	1.9	3
4	Primary CNS Lymphomas Prognosis. <i>Journal of Clinical Oncology</i> , 2007, 25, 4322-4324.	0.8	8
6	Primary Central Nervous System Lymphoma. <i>Neurologic Clinics</i> , 2007, 25, 1193-1207.	0.8	43
7	Primary Central Nervous System Lymphoma. <i>Seminars in Radiation Oncology</i> , 2007, 17, 223-229.	1.0	31
8	Treatment of primary central nervous system lymphoma. <i>Current Neurology and Neuroscience Reports</i> , 2007, 7, 191-199.	2.0	6
9	Treatment of primary central nervous system lymphoma. <i>Current Treatment Options in Neurology</i> , 2007, 9, 271-282.	0.7	7
10	High-dose chemotherapy supported by autologous stem cell transplantation in patients with primary central nervous system lymphoma: facts and opinions. <i>Leukemia and Lymphoma</i> , 2008, 49, 2042-2047.	0.6	45
11	Tattamento dei linfomi cerebrali primitivi. <i>EMC - Neurologia</i> , 2008, 8, 1-9.	0.0	0
12	Primary lymphoma of the central nervous system: epidemiology, pathology and current approaches to diagnosis, prognosis and treatment. <i>Leukemia and Lymphoma</i> , 2008, 49, 43-51.	0.6	116
14	Limited role of surgery in the management of primary central nervous system lymphoma (Review). <i>Oncology Reports</i> , 2009, 22, 439-49.	1.2	12
15	Therapeutic challenges in primary CNS lymphoma. <i>Lancet Neurology</i> , The, 2009, 8, 581-592.	4.9	86
16	Central nervous system dissemination in immunocompetent patients with aggressive lymphomas: incidence, risk factors and therapeutic options. <i>Hematological Oncology</i> , 2009, 27, 61-70.	0.8	70
17	Management of Immunocompetent Patients With Primary Central Nervous System Lymphoma. <i>Clinical Lymphoma and Myeloma</i> , 2009, 9, 353-364.	1.4	18
18	High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial. <i>Lancet</i> , The, 2009, 374, 1512-1520.	6.3	588
19	Primary CNS Lymphoma in Immunocompetent Patients. <i>Oncologist</i> , 2009, 14, 526-539.	1.9	114
20	Treatment approaches for primary CNS lymphomas. <i>Expert Opinion on Pharmacotherapy</i> , 2010, 11, 1263-1276.	0.9	15

#	ARTICLE	IF	CITATIONS
21	Primary Central Nervous System Lymphoma. <i>Current Treatment Options in Neurology</i> , 2010, 12, 347-359.	0.7	15
22	Primary CNS Lymphoma. <i>Blue Books of Neurology</i> , 2010, , 201-217.	0.1	0
23	High-dose methotrexate and rituximab with deferred radiotherapy for newly diagnosed primary B-cell CNS lymphoma. <i>Neuro-Oncology</i> , 2010, 12, 736-744.	0.6	83
24	Long-term follow-up of an age-adapted C5R protocol followed by radiotherapy in 99 newly diagnosed primary CNS lymphomas: a prospective multicentric phase II study of the Groupe d'Étude des Lymphomes de l'Adulte (GELA). <i>Annals of Oncology</i> , 2010, 21, 842-850.	0.6	56
25	Pharmacotherapy for Primary CNS Lymphoma. <i>CNS Drugs</i> , 2011, 25, 447-457.	2.7	7
26	Factors Influencing the Response to High Dose Methotrexate-based Vincristine and Procarbazine Combination Chemotherapy for Primary Central Nervous System Lymphoma. <i>Journal of Korean Medical Science</i> , 2011, 26, 551.	1.1	6
27	Primary central nervous system lymphoma. <i>Current Opinion in Neurology</i> , 2011, 24, 633-640.	1.8	14
28	Survival among patients with primary central nervous system lymphoma, 1973–2004. <i>Journal of Neuro-Oncology</i> , 2011, 101, 487-493.	1.4	72
31	Clinical characteristics and outcome of isolated extracerebral relapses of primary central nervous system lymphoma: a case series. <i>Hematological Oncology</i> , 2011, 29, 10-16.	0.8	23
32	Consolidation Radiotherapy in Primary Central Nervous System Lymphomas: Impact on Outcome of Different Fields and Doses in Patients in Complete Remission After Upfront Chemotherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011, 80, 169-175.	0.4	56
33	Modern concepts in the biology, diagnosis, differential diagnosis and treatment of primary central nervous system lymphoma. <i>Leukemia</i> , 2011, 25, 1797-1807.	3.3	157
34	V. Primary CNS lymphoma in immunocompetent patients. <i>Annals of Oncology</i> , 2011, 22, iv41-iv43.	0.6	3
35	Neuroendoscopic biopsy of ventricular tumors: a multicentric experience. <i>Neurosurgical Focus</i> , 2011, 30, E2.	1.0	81
36	Salvage Therapy for Refractory Aids-Related Primary Central Nervous System Lymphoma. <i>Case Reports in Oncological Medicine</i> , 2012, 2012, 1-4.	0.2	0
37	Primary central nervous system lymphoma. <i>Handbook of Clinical Neurology</i> / Edited By PJ Vinken and G W Bruyn, 2012, 105, 517-527.	1.0	4
38	Current and Emerging Pharmacotherapies for Primary CNS Lymphoma. <i>Clinical Medicine Insights: Oncology</i> , 2012, 6, CMO.S7752.	0.6	21
39	Pathogenesis and management of primary CNS lymphoma. <i>Expert Review of Anticancer Therapy</i> , 2012, 12, 623-633.	1.1	21
40	Primary CNS lymphoma. <i>Best Practice and Research in Clinical Haematology</i> , 2012, 25, 119-130.	0.7	52

#	ARTICLE	IF	CITATIONS
41	Appraisal of recent knowledge in primary central nervous system lymphoma. Memo - Magazine of European Medical Oncology, 2012, 5, 285-288.	0.3	0
42	Primary Central Nervous System Lymphoma. Hematology/Oncology Clinics of North America, 2012, 26, 897-916.	0.9	33
43	Treatment of primary CNS lymphoma (PCNSL) following successful treatment of systemic non-Hodgkin's lymphoma (NHL): a case series. Journal of Neuro-Oncology, 2013, 113, 27-32.	1.4	5
44	Rituximab, Methotrexate, Procarbazine, and Vincristine Followed by Consolidation Reduced-Dose Whole-Brain Radiotherapy and Cytarabine in Newly Diagnosed Primary CNS Lymphoma: Final Results and Long-Term Outcome. Journal of Clinical Oncology, 2013, 31, 3971-3979.	0.8	386
45	Diagnosis and treatment of primary CNS lymphoma. Nature Reviews Neurology, 2013, 9, 317-327.	4.9	166
46	Current uses of radiation therapy in patients with primary CNS lymphoma. Expert Review of Anticancer Therapy, 2013, 13, 1327-1337.	1.1	19
47	MATILDE chemotherapy regimen for primary CNS lymphoma. Neurology, 2014, 82, 1370-1373.	1.5	38
48	Primary central nervous system lymphoma: Current state of anti-CD20 therapy and appraisal of reported response criteria. Journal of Clinical Neuroscience, 2014, 21, 709-715.	0.8	9
49	Treatment of Primary CNS Lymphoma. Current Treatment Options in Neurology, 2014, 16, 277.	0.7	17
50	A phase I dose escalation study of idarubicin combined with methotrexate, vindesine, and prednisolone for untreated elderly patients with primary central nervous system lymphoma: The GOELAMS LCP 99 trial. American Journal of Hematology, 2014, 89, 1024-1029.	2.0	21
51	Oncology Scan's Primary Central Nervous System Lymphoma. International Journal of Radiation Oncology Biology Physics, 2014, 90, 721-724.	0.4	3
53	Immunochemotherapy for primary central nervous system lymphoma with rituximab, methotrexate, cytarabine and dexamethasone: Retrospective analysis of 18 cases. Molecular and Clinical Oncology, 2015, 3, 949-953.	0.4	7
54	Successful change of treatment strategy in elderly patients with primary central nervous system lymphoma by de-escalating induction and introducing temozolomide maintenance: results from a phase II study by The Nordic Lymphoma Group. Haematologica, 2015, 100, 534-540.	1.7	84
55	First-line treatment and outcome of elderly patients with primary central nervous system lymphoma (PCNSL) – a systematic review and individual patient data meta-analysis. Annals of Oncology, 2015, 26, 1305-1313.	0.6	152
56	What is the optimal dose of high-dose methotrexate in the initial treatment of primary central nervous system lymphoma?. Leukemia and Lymphoma, 2015, 56, 500-502.	0.6	6
57	High-dose chemotherapy and autologous stem cell transplant compared with conventional chemotherapy for consolidation in newly diagnosed primary CNS lymphoma – a randomized phase III trial (MATRix). BMC Cancer, 2016, 16, 282.	1.1	53
58	Endoscopic Reconstruction of CSF Pathways in Ventricular Tumors. Acta Neurochirurgica Supplementum, 2017, 124, 89-92.	0.5	1
59	Primary central nervous system lymphoma: essential points in diagnosis and management. Medical Oncology, 2017, 34, 61.	1.2	23

#	ARTICLE	IF	CITATIONS
60	Efficacy and safety of HD-MTX based systemic chemotherapy regimens: retrospective study of induction therapy for primary central nervous system lymphoma in Chinese. Scientific Reports, 2017, 7, 17053.	1.6	10
61	Methotrexate plus idarubicin improves outcome of patients with primary central nervous system lymphoma. Oncotarget, 2017, 8, 53701-53713.	0.8	4
62	Balancing relapses versus cognitive impairment in primary central nervous system lymphoma: a single-center experience. Hematology, 2018, 23, 385-390.	0.7	6
63	Evaluation of Memorial Sloan-Kettering Cancer Center and International Extranodal Lymphoma Study Group prognostic scoring systems to predict Overall Survival in intracranial Primary CNS lymphoma. Brain and Behavior, 2018, 8, e00928.	1.0	28
64	Is whole-brain radiotherapy still a standard treatment for primary central nervous system lymphomas?. Current Opinion in Neurology, 2018, 31, 733-739.	1.8	18
65	Chemotherapy for Primary Central Nervous System Lymphoma. , 2018, , 455-468.		0
66	Primary Central Nervous System Lymphoma. Neurologic Clinics, 2018, 36, 517-532.	0.8	13
67	Primary CNS Lymphomas: Challenges in Diagnosis and Monitoring. BioMed Research International, 2018, 2018, 1-16.	0.9	76
68	Treatment outcome and prognostic factors in PCNSL. Diagnostic Pathology, 2019, 14, 56.	0.9	24
69	Educational Updates in Hematology Book: 25th Congress of the European Hematology Association, Virtual Edition 2020. HemaSphere, 2020, 4, .	1.2	2
70	High-dose methotrexate-based regimens and post-remission consolidation for treatment of newly diagnosed primary CNS lymphoma: meta-analysis of clinical trials. Scientific Reports, 2021, 11, 2125.	1.6	23
71	Primary treatment and recent survival trends in patients with primary diffuse large B-cell lymphoma of central nervous system, 1995-2016: A population-based SEER analysis. Hematological Oncology, 2023, 41, 248-256.	0.8	3
72	Lymphomes intra-oculaires. , 2010, , 565-586.		1
73	Primary Central Nervous System Lymphoma. Medical Radiology, 2008, , 461-470.	0.0	0
74	LNH cÃ©rÃ©bral. , 2010, , 47-54.		0
76	Primary Central Nervous System Lymphoma: Systemic Relapse. , 2012, , 13-20.		0
77	CNS Lymphoma. , 2014, , 207-223.		0
79	Apparent diffusion coefficient as a valuable quantitative parameter for predicting clinical outcomes in patients with newly diagnosed primary CNS lymphoma. Blood Research, 2020, 55, 99-106.	0.5	9

#	ARTICLE	IF	CITATIONS
82	A Systematic Review of High-Dose Methotrexate for Adults with Primary Central Nervous System Lymphoma. <i>Cancers</i> , 2023, 15, 1459.	1.7	7